Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for BioCorRx (BICX) over the last 12 years, with Q1 2024 value amounting to $4045.0.

  • BioCorRx's Non-Current Deffered Revenue changed 0.0% to $4045.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $4045.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $4045.0 for FY2023, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2024, BioCorRx's Non-Current Deffered Revenue is $4045.0, which was down 0.0% from $4045.0 recorded in Q4 2023.
  • BioCorRx's 5-year Non-Current Deffered Revenue high stood at $1.2 million for Q2 2020, and its period low was $4045.0 during Q4 2022.
  • Its 5-year average for Non-Current Deffered Revenue is $163201.0, with a median of $28675.0 in 2022.
  • In the last 5 years, BioCorRx's Non-Current Deffered Revenue surged by 58402.73% in 2020 and then plummeted by 9523.55% in 2021.
  • Quarter analysis of 5 years shows BioCorRx's Non-Current Deffered Revenue stood at $72281.0 in 2020, then crashed by 48.39% to $37301.0 in 2021, then crashed by 89.16% to $4045.0 in 2022, then changed by 0.0% to $4045.0 in 2023, then changed by 0.0% to $4045.0 in 2024.
  • Its Non-Current Deffered Revenue was $4045.0 in Q1 2024, compared to $4045.0 in Q4 2023 and $4045.0 in Q3 2023.